Skip to main content
placeholder image

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2019

Citation


  • Powderly, J. D., de Souza, P. L., Gutierrez, R., Horvath, L., Seitz, L., Ashok, D., . . . Chaudhry, A. (2019). AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.. Journal of Clinical Oncology, 37(15_suppl), 2604. doi:10.1200/jco.2019.37.15_suppl.2604

Web Of Science Accession Number


Start Page


  • 2604

End Page


  • 2604

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2019

Citation


  • Powderly, J. D., de Souza, P. L., Gutierrez, R., Horvath, L., Seitz, L., Ashok, D., . . . Chaudhry, A. (2019). AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.. Journal of Clinical Oncology, 37(15_suppl), 2604. doi:10.1200/jco.2019.37.15_suppl.2604

Web Of Science Accession Number


Start Page


  • 2604

End Page


  • 2604

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication